A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 285 participants.

Also called NCT05769608

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 285 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05769608
Other papers using this trial's data
  • Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension The New England journal of medicine, 2025-05-08 DOI, PubMed 40267417

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05769608. Randomized; double masking; primary purpose treatment. Start 2023-03-13 (actual); primary completion 2025-01-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
Condition
Hypertension
Intervention (Drug)
Placebo
Intervention (Drug)
lorundrostat Dose 1
Intervention (Drug)
lorundrostat Dose 2
Lead sponsor
Mineralys Therapeutics Inc. (class: industry)

Record details

Record id
cardio:ct-nct05769608
Content hash
d2436d84e68d4e39b6419274327e5a318219f8069393569df3447ed4e927bcc2